KUALA LUMPUR: Ekuiti Nasional Bhd (Ekuinas) has acquired an 80 per cent stake in Symbiotica Speciality Ingredients Sdn Bhd (Symbiotica), a leading homegrown active pharmaceutical ingredient (API) manufacturer in Southeast Asia (SEA).
KUALA LUMPUR: Ekuiti Nasional Bhd’s (Ekuinas) total cumulative investment stood at RM4.4bil in FY21, comprising 70 investments covering 47 direct investments and 23 outsourced programmes which consequently generated a total economic deployment of RM5bil, together with private sector partners.
Ekuinas records strong investment returns for 2020 thestar.com.my - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thestar.com.my Daily Mail and Mail on Sunday newspapers.
Ekuinas chief executive officer Syed Yasir Arafat Syed Abd Kadir said Ekuinas’ entry into the healthcare and pharmaceutical space was timely as it looked to capitalise on global megatrends and demographic shifts amid the emergence of Covid-19.
KUALA LUMPUR: Ekuiti Nasional Bhd (Ekuinas) made its foray into the pharmaceutical industry with the acquisition of a controlling stake in Medispec (M) Sdn Bhd.
The government-linked private equity fund management company said the acquisition was based on an enterprise value of RM88.5mil.
Ekuinas chief executive officer Syed Yasir Arafat Syed Abd Kadir said Ekuinas’ entry into the healthcare and pharmaceutical space was timely as it looked to capitalise on global megatrends and demographic shifts amid the emergence of Covid-19.